An official website of the United States government
CAB-AXL-ADC Safety and Efficacy Study in Adults With NSCLC
Trial Status: complete
The objective of this study is to assess safety and efficacy of CAB-AXL-ADC in NSCLC
Inclusion Criteria
Patients must have measurable disease.
Age ≥ 18 years
Adequate renal function
Adequate liver function
Adequate hematological function
Have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
Life expectancy of at least three months.
Exclusion Criteria
Patients must not have clinically significant cardiac disease.
Patients must not have known non-controlled CNS metastasis.
Patients must not have had prior therapy with a conjugated or unconjugated auristatin derivative/vinca-binding site targeting payload.
Patients must not have a history of ≥ Grade 3 allergic reactions to mAb therapy as well as known or suspected allergy or intolerance to any agent given during this study.
Patients must not have had major surgery within 4 weeks before first BA3011
Patients must not have known human immunodeficiency virus (HIV) infection, active hepatitis B and/or hepatitis C.
Patients must not be women who are pregnant or breast feeding.
Additional locations may be listed on ClinicalTrials.gov for NCT04681131.
Locations matching your search criteria
United States
Pennsylvania
Pittsburgh
University of Pittsburgh Cancer Institute (UPCI)
Status: Active
Name Not Available
South Carolina
Charleston
Medical University of South Carolina
Status: Temporarily closed to accrual
Name Not Available
This is a multi-center, open-label, Phase 2 study designed to evaluate the safety,
tolerability, PK, immunogenicity, and antitumor activity of BA3011, a conditionally
active biologic (CAB) AXL-targeted antibody drug conjugate (CAB-AXL-ADC), alone and in
combination with PD-1 inhibitor in patients with metastatic non-small cell lung cancer
